Back to Search Start Over

Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer.

Authors :
Alcantar-Orozco EM
Gornall H
Baldan V
Hawkins RE
Gilham DE
Source :
Human gene therapy methods [Hum Gene Ther Methods] 2013 Oct; Vol. 24 (5), pp. 310-20. Date of Electronic Publication: 2013 Aug 24.
Publication Year :
2013

Abstract

The genetic modification of peripheral blood lymphocytes using retroviral vectors to redirect T cells against tumor cells has been recently used as a means to generate large numbers of antigen-specific T cells for adoptive cell therapy protocols. However, commonly used retroviral vector-based genetic modification requires T cells to be driven into cell division; this potent mitogenic stimulus is associated with the development of an effector phenotype that may adversely impact upon the long-term engraftment potential and subsequent antitumor effects of T cells. To investigate whether the cytokines used during culture impact upon the engraftment potential of gene-modified T cells, a humanized model employing T cells engrafted with a MART-1-specific T cell receptor adoptively transferred into NOD/Shi-scid IL-2rγ(-/-) (NSG) immune-deficient mice bearing established melanoma tumors was used to compare the effects of the common γ chain cytokines IL-2, IL-7, and IL-15 upon gene-modified T cell activity. MART-1-specific T cells cultured in IL-7 and IL-15 demonstrated greater relative in vitro proliferation and viability of T cells compared with the extensively used IL-2. Moreover, the IL-15 culture prolonged the survival of animals bearing melanoma tumors after adoptive transfer. However, the combination of IL-7 and IL-15 produced T cells with improved engraftment potential compared with IL-15 alone; however, a high rate of xenogeneic graft-versus-host disease prevented the identification of a clear improvement in antitumor effect of these T cells. These results clearly demonstrate modulation of gene-modified T cell engraftment in the NSG mouse, which supports the future testing of the combination of IL-7 and IL-15 in adoptive cell therapy protocols; however, this improved engraftment is also associated with the long-term maintenance of xenoreactive T cells, which limits the ultimate usefulness of the NSG mouse model in this situation.

Details

Language :
English
ISSN :
1946-6544
Volume :
24
Issue :
5
Database :
MEDLINE
Journal :
Human gene therapy methods
Publication Type :
Academic Journal
Accession number :
23931270
Full Text :
https://doi.org/10.1089/hgtb.2013.022